# Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)

Source: https://onco.cc/trials/nct07134101/  
OnCo record `nct07134101` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab and bevacizumab (glioblastoma use) in colorectal cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.

## Summary

Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) is a phase 2, randomised interventional study registered as NCT07134101 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 138 participants, started 2025-09-01 and due to reach its primary completion in 2028-08-31. Interventions recorded: Serplulimab; Bevacizumab; Short-Course Radioterapy; Chemotherapy (CAPOX or capecitabine). Conditions listed: Colorectal Cancer (Diagnosis). Primary outcome: Complete Remission (CR) Rate assessed by pathology, MRI, endoscopy, and clinical examination. Colorectal eligibility wording from the registry: "Diagnosis: Pathologically confirmed rectal adenocarcinoma with proficient mismatch repair (pMMR) / microsatellite stable (MSS) status, based on biopsy of the primary tumor". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: SMARTi-RC01
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07134101
- Phase: 2
- Setting: Neoadjuvant Chemoradiotherapy Combined With Serplulimab With or Without Bevacizumab for Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Phase II Randomized Trial
- Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT07134101: https://clinicaltrials.gov/study/NCT07134101

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07134101.json